MLL-rearranged Acute Lymphoblastic Leukemia (ALL) represents an unfavorable type of leukemia that often is highly resistant to glucocorticoids like prednisone and dexamethasone. As the response to prednisone largely determines the clinical outcome of pediatric ALL patients, overcoming resistance to this drug may be an important step towards improving prognosis. Here we show how gene expression profiling identifies high-level MCL-1 expression to be associated with prednisolone resistance in MLL-rearranged infant ALL, as well as in more favorable types of childhood ALL. To validate this observation, we determined MCL-1 expression using quantitative RT-PCR in a cohort of MLL-rearranged infant ALL and pediatric non-infant ALL samples, and confirmed that high-level MCL-1 expression is associated with prednisolone resistance in vitro. Also, MCL-1 expression appeared to be significantly higher in MLL-rearranged infant patients who showed a poor response to prednisone in vivo as compared with prednisone good responders. Finally, down-regulation of MCL-1 in prednisolone resistant MLL-rearranged leukemia cells by RNA interference, to some extent led to prednisolone sensitization. Collectively, our findings suggest a potential role for MCL-1 in glucocorticoid resistance in MLL-rearranged infant ALL, but at the same time strongly imply that highlevel MCL-1 expression is not the sole mechanism providing resistance to these drugs.
Introduction
Acute Lymphoblastic Leukemia (ALL) in infants (i.e. children less than 1 year of age) is characterized by an exceptionally high incidence (~80% of the cases) of chromosomal translocations affecting the MLL gene. 1, 2 These chromosomal abnormalities, believed to be initiating events in leukemogenesis, usually involve reciprocal translocations fusing the N-terminal portion of the MLL gene to the Cterminal region of one of its translocation partner genes, of which over 50 have been described. 3, 4 The presence of MLL rearrangements represents the most important independent predictor of an adverse outcome. 1, 5 While current therapies for pediatric ALL in general result in long-term survival in >80% of the cases, these therapies fail in >50% of infants diagnosed with MLL-rearranged ALL. 1 A major obstacle hampering successful treatment results in MLL-rearranged infant ALL is cellular resistance to several drugs used in the treatment of ALL. In vitro studies showed that MLLrearranged infant ALL cells are particularly highly resistant to prednisolone, 6 the spearhead drug of ALL treatment regimes. Moreover, ~30% of the MLL-rearranged infant ALL patients show a poor prednisone response in vivo, defined as the presence of ≥1000 leukemic blasts/μL after a 7-day window of prednisone mono-therapy. 1, 7 In contrast, among children older than 1 year of age (noninfants) diagnosed with ALL, less than 10% of the patients show a poor in vivo response to prednisone. 8 Both in vitro prednisolone sensitivity as well as the in vivo prednisone response are predictive for clinical outcome in pediatric ALL in general. 7, 9, 10 Thus, the poor prognosis for MLLrearranged ALL may to a large extent be associated with prednisone resistance. Therefore, overcoming resistance to this drug may be an important step towards a more favorable prognosis for MLL-rearranged leukemias.
Comparing gene expression profiles of pediatric ALL patients (above the age of 1 year) either in vitro sensitive or resistant to prednisolone, we recently found increased expression of the antiapoptotic BCL-2 family member MCL-1 in prednisolone resistant patients samples. 11 MCL-1 is considered an important cell survival factor in peripheral blood B-lymphocytes, 12 and is often overexpressed in hematopoietic malignancies including B-cell Chronic Lymphoblastic Leukemia (CLL) and
Multiple Myeloma (MM). 13, 14 Here we show that increased MCL-1 expression is not only associated with in vitro prednisolone resistance in pediatric ALL but also prominently in MLL-rearranged infant ALL. MCL-1 expression appears to be one of the few overlapping genes that commonly discriminates between prednisolone resistance and sensitivity when gene expression signatures associated with
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From prednisolone resistance for both of these patient groups are compared. Furthermore we demonstrate that among MLL-rearranged infant ALL patients elevated MCL-1 expression is predictive for both the in vitro prednisolone as well as to some extent for the in vivo prednisone response. Finally we demonstrate that reducing MCL-1 protein expression moderately sensitizes prednisolone-resistant
MLL-rearranged leukemia cells to this drug in vitro.
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Materials and Methods

Patient samples.
Untreated primary bone marrow and/or peripheral blood samples from infants (<1 year of age) diagnosed with ALL were collected at the Erasmus MC -Sophia Children's Hospital and other hospitals participating in the INTERFANT-99 treatment study. 1 Samples from pediatric ALL patients older than 1 year of age (non-infants) were obtained from our cell bank at the Erasmus MC -Sophia
Children's Hospital. Approval for these studies was obtained from the Erasmus MC Institutional Review Board. Informed consent was obtained according to the Declaration of Helsinki.
Within 24 hours after sampling, mononuclear cells were isolated by density gradient centrifugation using Lymphoprep (density 1.077 g/ml ; Nycomed Pharma, Oslo, Norway), and resuspended in RPMI 1640 medium (Dutch modification without L-glutamine; Invitrogen life technologies, Breda The Netherlands) supplemented with 20% fetal calf serum (FCS; Integro, Zaandam, The Netherlands), 2 mM L-glutamine (Invitrogen) 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml sodium selenite (ITS media supplement; Sigma, St Louis MO, USA), 100 IU/ml penicillin, 100 μg/ml streptomycin, 0.125 μg/ml fungizone and 0.2 mg/ml gentamycin (Invitrogen). Contaminating non-leukemic cells were removed using immunomagnetic beads as described elsewhere. 15 All samples used contained >90% leukemic cells, as determined morphologically on May-Grünwald-Giemsa (Merck, Darmstadt, Germany) stained cytospins.
As part of the INTERFANT-99 study, the infant ALL samples were screened for the presence of MLL rearrangements by FISH analysis, and the type of translocation was determined using PCR analysis . 1 An overview of available patient characteristics and clinical parameters are listed in Supplemental table 1 .
In vitro prednisolone cytotoxicity and in vivo prednisone response.
In vitro prednisolone (Bufa, Uitgeest, The Netherlands) cytotoxicity was determined using the MTT assay as extensively described before. 16 The in vivo response to prednisone in infant ALL patients was determined after a 7-day window of prednisone mono-therapy (prior to combination chemotherapy) as part of the INTERFANT-99 treatment protocol. 1 Patients are defined as prednisone poor responders (PPRs) when ≥1000 leukemic blasts/μL peripheral blood remain present after the 7-For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From day prednisone window. In cases where the amount of leukemic blasts drops below 1000/μL, the patients are defined as prednisone good responders (PGRs).
Microarray analysis of prednisone-sensitive and prednisone-resistant ALL samples
Patient samples were characterized as in vitro sensitive or resistant to prednisolone based on the LC 50 value (i.e. the concentration of prednisolone lethal to 50% of the leukemic cells), as obtained from MTT assays (described above). Samples were defined as prednisolone-sensitive at LC 50 values <0.1 ug/mL prednisolone, and prednisolone-resistant at LC 50 values >150 ug/mL prednisolone. Gene expression data (Affymetrix HU133A microarrays) were normalized using dChip, 17 and filtered with a max-min=100, and max/min=4. The probe sets that correlated with sensitive/resistant distinction were determined using a signal-to-noise statistic and permutation testing. The accuracy of the gene expression signatures were assessed using a cross-validation approach as described previously. 18 Briefly, for both the infant and non-infant ALL signatures separately, one sample was withheld and the specified number of probe sets that best correlated with the prednisolone sensitive/resistant class distinction were identified. Next, the class of the withheld sample was determined based on the gene expression pattern of the probe sets identified in this manner. This process was repeated for all samples and the error rate in class prediction was determined and plotted against the number of probe sets used to build the model. The models were generated using 1 to 65 probe sets. The raw microarray data are listed in Supplemental Table 2 . All microarray data can be found in the GEO public database under accession number GSE19143.
Quantitative real-time PCR (TaqMan) analysis
Total RNA was extracted from a minimum of 5 x10 6 leukemic cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions, and quantified on a spectrophotometer. The integrity of the extracted RNA was assessed on 1% agarose gels. Extracted RNA was reverse transcribed and the obtained cDNA was used to quantify MCL-1 mRNA expression relative to the endogenous housekeeping gene RNaseP, using quantitative real-time PCR (TaqMan©) as described previously. 
Cell line culture
Both SEMK2 and MV4-11 cells were maintained in RPMI 1640 with L-Alanyl-L-Glutamine (Invitrogen) supplemented with 10% FCS (Integro), 100 IU/ml penicillin, 100 μg/ml streptomycin and 0.125 μg/ml fungizone (Invitrogen) and grown as suspension cultures at 37°C in humidified air containing 5% CO 2 .
The SEMK2 represents a B-lineage MLL-rearranged ALL cell line 20 , and MV4-11 is an MLLrearranged Acute Myeloid Leukemia (AML) cell line. Both cell lines harbor MLL translocation t (4;11) and are highly resistant to prednisolone in vitro.
RNA interference
MCL-1 knock-down in the prednisone-resistant MLL-rearranged ALL and AML cell lines SEMK2 and MV4-11 were performed essentially as described before. 21 Briefly, the RNA interference sequence for human MCL-1, GGACTGGCTAGTTAAACAAAG, as well as a validated non-silencing control (RHS1707; Openbiosystems) were cloned in to the pPRIME-SFFV-GFP lentiviral vector which enables the efficient expression of shRNAs in hematopoietic cells from the RNA Polymerase II promoter SFFV.
The vector contains a GFP that allows for marking of lentiviral integration. Virus was produced by transient transfection of 293FT with a 3:1:4 mixture of psPAX-2, pMD2G-VSVG (kind gifts of Dr. D.
Trono, University of Geneva) and pPRIME-SFFV-GFP. After 24 hours medium was refreshed and virus-containing medium was harvested 48 hours after transfection. Upon filtration through a 0.45 μm cellulose acetate filter, the virus stock was used to infect SEMK2 or MV4-11 cells. Infected cells were analyzed for MCL-1 expression by immunoblotting, and the in vitro prednisolone sensitivity was determined by 2-day MTT assays performed in triplicate. These procedures were then repeated in order to establish reproducibility among independent experiments.
Immunoblotting SDS-PAGE and immunoblotting were performed essentially as described earlier. 21 Total cellular protein lysates were resolved on polyacrylamide gels and transferred to a nitrocellulose membrane 
Results
Microarray analysis of prednisone-sensitive and prednisone-resistant ALL samples.
Comparing gene expression profiles between prednisolone-resistant and prednisolone-sensitive pediatric ALL patients revealed gene expression signatures associated with prednisolone resistance for both non-infant (>1 year of age) or infant (<1 year of age) ALL ( Figure 1A ). However, assessment of the accuracy of these signatures to predict prednisolone resistance or sensitivity using a crossvalidation approach showed that, in particular in the infant ALL signature, the accuracy was rather low ( Figure 1B) . In other words, the error rate of re-assigning infant ALL samples to their original class (i.e. prednisolone sensitive or resistant) after being withheld from the analysis, tended to be ~30% ( Figure   1B ), presumably due to the relatively low numbers of patient samples used to build these signatures.
Therefore, we decided to merge both signatures in search for overlapping genes associated with prednisolone resistance in both patient groups. As shown in Figure 1C , elevated expression of Solute carrier 2 (SLC2), Fos-like antigen 2 (FOSL2), and MCL-1 appeared to be characteristic for both prednisolone-resistant infant as well as prednisolone-resistant non-infant ALL samples. Whereas both MCL-1 and SLC2 occurred in the top50 of up-regulated genes associated with prednisolone resistance in both the infant and non-infant ALL signatures ( Figure 1A ), this was not the case for FOSL2. Our approach to merge both signatures in search of genes that are associated with prednisolone resistance in both infant and non-infant ALL cases was not limited to the most significantly differentially expressed genes in both patient groups, but included the entire datasets.
MCL-1, SLC2
and FOSL2 may therefore not be the most significantly up-regulated genes in either the infant or non-infant ALL signatures when evaluated separately, but do represent the few genes associated with prednisolone resistance in both patient groups.
Correlation between high-level MCL-1 expression and in vitro resistance to prednisolone.
To validate our microarray data, we determined MCL-1 mRNA expression in MLL-rearranged infant ALL (n=23) and non-infant ALL (n=20) samples using quantitative real-time PCR (TaqMan). For the sake of uniformity, infant ALL samples not carrying translocations of the MLL gene were intentionally excluded from these experiments, as the prognosis (and therapy response) of these patients are significantly more favorable as compared to MLL-rearranged infant ALL patients. Among both patient For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From groups, we observed a wide and continuous range of MCL-1 expression levels (Figure 2A and 2C ).
Using the median or mean MCL-1 expression as a cut-off, we divided the samples into two groups either expressing "high" or "low" MCL-1 levels. For the MLL-rearranged infant ALL patients the median expression coincided with the mean expression value. Next, we compared the in vitro prednisolone response between patients displaying high or low MCL-1 expression among both patient groups separately. As expected, MLL-rearranged infant ALL and pediatric non-infant ALL samples displaying high MCL-1 expression were significantly (p<0.05) more resistant to prednisolone as compared to patients expressing lower levels of MCL-1 ( Figure 2B and 2D) . Interestingly, high level MCL-1 expression was also associated with the glucocorticoid dexamethasone (closely related to prednisolone), but not with increased resistance to unrelated drugs like L-asparaginase, vincristine, daunorubicin and cytarabine (Ara-C) (Supplemental Figure 1 ).
Correlation between high-level MCL-1 expression and in vivo prednisone resistance.
The 7-day window of prednisone monotherapy (prior to the combination chemotherapy) implemented in the INTERFANT-99 treatment protocol and used to ascribe infant ALL patients to either the standard-risk (GPR; good prednisone response) or high risk (PPR; poor prednisone response) arm of the protocol, provided an opportunity to correlate MCL-1 expression levels with the in vivo prednisone response in MLL-rearranged infant ALL patients. This revealed that the MCL-1 expression is significantly (p=0.031) higher in MLL-rearranged infant ALL patients with a poor prednisone response in vivo ( Figure 3A ). Of note is that the three patients with the highest MCL-1 expression appeared to have shown a good prednisone response in vivo ( Figure 3A) . However, despite their favorable in vivo prednisone response, these patients all relapsed, two of which within the first year upon diagnosis.
Nevertheless, a clear relationship between the level of MCL-1 expression and clinical outcome or risk of relapse was not found, possibly due to the low numbers of patient samples for which these data was available. Moreover, the correlation between in the in vitro prednisolone and in vivo prednisone response was definitely not absolute, as some patients showing a poor prednisone response in vivo appeared sensitive to prednisolone in vitro, and vice versa. Figure 3B 
, but also demonstrate that the MCL-1 expression in MLL-rearranged infant ALL patients that are sensitive to prednisolone in vitro and respond well to prednisone in vivo, is markedly reduced as compared to more resistant patients.
Down-regulation of MCL-1 induces sensitivity to prednisolone.
To determine whether MCL-1 protein down-regulation in prednisolone resistant leukemia cells reverses the resistant phenotype and induces prednisolone sensitivity, we knocked-down MCL-1 expression in the MLL-rearranged ALL and AML cell lines SEMK2 and MV4-11 using RNA interference (RNAi). As shown in Figure 4A 
Discussion
MLL-rearranged ALL represents an aggressive and difficult to treat type of leukemia commonly diagnosed in children less than 1 year of age (i.e. infants). Despite various attempts to intensify therapy in order to improve prognosis for these very young children, survival rates remain at best ~50%.
1 Significantly contributing to this poor prognosis is cellular drug resistance. Leukemic cells from MLL-rearranged infant ALL patients are highly resistant, both in vitro and in vivo, to glucocorticoids (like prednisone and dexamethason) which form the backbone of ALL treatment protocols. Since it has been established that both the in vitro prednisolone and in vivo prednisone response are highly predictive for clinical outcome among ALL patients 7, 9, 10 , overcoming glucocorticoid resistance may be an important step towards an improved outcome for MLL-rearranged ALL. For this the biological mechanism(s) that maintain resistance to these drugs should be elucidated and understood in order to be able to modulate glucocorticoid resistance.
Here we show that high-level expression of the anti-apoptotic BCL-2 family member MCL-1, is associated with in vitro prednisolone resistance in both MLL-rearranged infant ALL, as well as in noninfant pediatric ALL. The fact that high-level MCL-1 expression appeared to be associated with in vitro prednisolone resistance in both of these patient groups indicates that this may involve a general resistance mechanism protecting ALL cells from glucocorticoid induced apoptosis. In subsequent experiments focusing on MLL-rearranged infant ALL samples, we confirmed that patients expressing high levels of MCL-1 not only are significantly more resistant in vitro to prednisolone, but also to the closely related glucocorticoid dexamethasone (Supplemental Figure 1) . Furthermore, we demonstrate that, to some extent, high-level MCL-1 expression was associated with a poor response to prednisone in vivo. However, the range of MCL-1 expression in both the prednisone good and poor responders is pronounced, and the three patients expressing the highest levels of MCL-1 appeared to be have experienced a good in vivo response to prednisone. This indicates that, despite of the tendency of patients with a poor in vivo prednisone response expressing higher levels of MCL-1, the correlation is not entirely conclusive, suggesting that high-level MCL-1 expression may not be the sole mechanism driving prednisone resistance in vivo. Supplemental table 2 ). An alternative interpretation of this observation could be that modulation of prednisolone resistance alone may not be sufficient to significantly improve prognosis.
To validated the role of MCL-1 expression in maintaining prednisolone resistance in vitro, we conducted MCL-1 knock-down experiments, demonstrating that prednisolone resistant MLLrearranged ALL (SEMK2) cells become more sensitive to this drug when MCL-1 protein expression is markedly reduced. In MLL-rearranged AML (MV4-11) cells however, MCL-1 protein expression was markedly higher, and MCL-1 protein expression could only be reduced for about 50%. Consequently, the prednisolone sensitizing effects in these cells were only moderate. Collectively, these results clearly demonstrate that merely reducing the levels of MCL-1 expression is sufficient to completely reverse the prednisolone-resistant phenotype. Again, these observations emphasize that up-regulated MCL-1 expression presumably is not the only mechanism maintaining prednisolone resistance in MLLrearranged infant ALL (see below).
As a member of the anti-apoptotic BCL-2 protein family, MCL-1 may be expected to raise resistance to apoptosis induced by various chemotherapeutic drugs. However, we observed that elevated MCL-1 expression is only associated with resistance to the glucocorticoids prednisolone and dexamethasone, but not with resistance to other drugs used in the treatment of ALL like vincristine, Lasparaginase, daunorubicine and Ara-C (cytarabine) (Supplemental Figure 1) . A possible explanation for this remarkable phenomenon may lie in both the mechanism by which MCL-1 exerts its antiapoptotic function and the way in which glucocorticoids induce apoptosis. Glucocorticoids specifically trigger apoptosis by inducing Ca 2+ release from the endoplasmic reticulum (ER) and thereby increase the intracellular Ca 2+ levels. Taken together, our study demonstrates an important role of MCL-1 in glucocorticoid resistance in MLL-rearranged infant ALL, warranting further studies to identify drugs that effectively down-regulate MCL-1 expression, to be co-administered during glucocorticoid-based treatment regimes. Our observations also strongly suggest that high-level MCL-1 expression presumably is not the sole mechanism maintaining glucocorticoid resistance, and additional studies in search for alternative or co-operating mechanisms remain important to fully understand and eventually circumvent or overcome glucorticoid resistance in patients.
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Kaiser N, Edelman IS. A. Shows the top 50 of up-regulated probe sets correlating to either prednisone resistance or sensitivity in non-infant (>1 year of age) (n=27) and infant (< 1 year of age) (n=25) pediatric ALL patients. Raw microarray data can be found in Supplemental Table 1 The difference between patient groups was statistically analyzed using the Mann-Whitney U test. 
